No abstract

Metabolic studies of ipriflavone (TC-80) in rats by gas-liquid chromatography-mass spectrometry led to the characterization of the following metabolites: the parent compound, 7-hydroxy-3-phenyl-4H-1-benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4one, 3-(4-hydroxyphenyl)-7-isopropoxy-4H-1-benzopyran-4-one, 2-(3-phenyl-4-oxo-4H-1-benzopyran-7-yl)oxypropionic acid, 2-•k3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl•l oxypropionic acid and 2-•k3-(3-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl•l oxypropionic acid. From the metabolites identified, TC-80 was shown to be metabolized primarily by oxidation. In vitro study using tissue slices of rats indicated that the above metabolic changes occurred exclusively in the liver. It was also demonstrated that the compound did not undergo metabolic conversion by gut flora of rats.

No abstract

Oral 14C-ipriflavone was absorbed by rats to give a maximum plasma 14C level at 1.5h and a half-life of 5.8h. In dogs, after po dosing, the plasma 14C peaked at 0.5h, followed by gradual decline. The plasma of both animals contained mostly metabolites, with small amounts of unchanged Ipriflavone. In rats, 14C was distributed widely in tissues, with relatively high concns. in the liver, kidney and gut. Distribution in rat thigh bone of unmetabolized ipriflavone was also demonstrated. 14C-Ipriflavone was eliminated mostly as metabolites within 48 and 72h, respectively, in rats and dogs. Rats excreted more 14C in urine than in feces, whereas the reverse was noted in dogs. Biliary excretion and reabsorption of 14C were also obvious in both animals.

No abstract